Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | HBB | P68871 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL18534 | 0.92 | MEN1 (0.82) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL7406346 | 0.91 | MEN1 (0.71) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL270 | 0.89 | MEN1 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL5948996 | 0.89 | MEN1 (0.77) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL28796595 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL14687482 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 | |
| Phenazopyridine SCHEMBL215655 | 0.85 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373245-B1 | INTERMEDIATES FOR PRODUCING SPINOSYNS | BAYER CROPSCIENCE AG (DE) | 2006-12-27 | — | — | EP | claimed |
| WO-2004106343-A2 | AGELASTATIN DERIVATIVES OF ANTITUMOUR AND GSK-3BETA-INHIBITING ALKALOIDS | UFC LIMITED (GB) | 2004-12-09 | — | — | WO | claimed |
| US-20040147766-A1 | Intermediates for producing spinosyns | BAYER CROPSCIENCE AG (DE) | 2004-07-29 | — | — | US | claimed |
| US-5750794-A | Process for preparing chiral tetralone | PFIZER INC. (US) | 1998-05-12 | — | — | US | claimed |
| JP-5339252-A | — | — | None | — | — | JP | disclosed |
| US-20240060096-A1 | COMPOSITIONS AND METHODS FOR PRODUCING 1,8-DIHYDROXYNAPHTHALENE AND CYCLIC HYDROCARBONS FROM 1,8-DIHYDROXYNAPHTHALENE | TECH HOLDING LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3891165-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891166-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891164-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-4707489-A | TERMITES, CRICKETS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-11-17 | — | — | US | disclosed |
| EP-0161921-A2 | Improvements relating to pesticides | BTG INTERNATIONAL LIMITED (GB) | 1985-11-21 | — | — | EP | disclosed |
| EP-0161492-A2 | Estrogen synthesis inhibitors | THE ROCKEFELLER UNIVERSITY (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4546098-A | ANTIESTROGENS; HORMONE INHIBITORS | THE ROCKEFELLER UNIVERSITY (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0072111-B1 | SYNTHETIC PHOSPHOLIPID COMPOUNDS AND THEIR PREPARATION | LIPID SPECIALTIES, INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0145875-A2 | Gamma-aminobutyric acid transaminase inhibitors and processes for their preparation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4426330-A | Synthetic phospholipid compounds | LIPID SPECIALTIES, INC. (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0072111-A1 | Synthetic phospholipid compounds and their preparation | LIPID SPECIALTIES, INC. (US) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147766-A1 | Intermediates for producing spinosyns | SPIN4, SPIN3, FDPS | MEN1 2196/4885KMT2A 3432/4885MAPT 2180/4885 |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | MEN1 1602/4885KMT2A 3097/4885MAPT 4830/4885 |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | MEN1 1573/4885KMT2A 3101/4885MAPT 4828/4885 |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | MEN1 1605/4885KMT2A 3091/4885MAPT 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.